Table 1.
Baseline characteristics of the studies.
| Studies (year) |
Groups | n | Age (years) |
Men (%) | DM (%) | Prior Ml (%) | LVEF (%) | Aspirin (%) | β-blockers (%) | Statins (%) | CCB (%) | ACEI/ARB (%) | Stenotic vessels >50% (mean) |
Stent (%) | DES (%) | Follow-up (months) |
CRoBa |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BARI-2D (2005)7 | PCI | 1176 | 62.3 | 70.4 | 100.0 | 31.7 | 57.0 | 93.5 | 83.9 | 94.6 | - | 91.2 | - | 90.0 | 35.0 | 5 | ***** |
| MT | 1192 | 62.4 | 70.3 | 100.0 | 32.4 | 57.3 | 94.2 | 87.9 | 95.4 | - | 92.0 | - | |||||
| OAT (2006)7 | PCI | 1082 | 58.6 | 78.0 | 18.0 | 12.0 | 47.4 | 94.0 | 86.0 | 80.0 | 65.0 | 80.0 | - | 87.0 | 8.0 | 4 | ***** |
| MT | 1084 | 58.7 | 78.0 | 23.0 | 11.0 | 48.0 | 97.0 | 89.0 | 82.0 | 61.0 | 80.0 | - | |||||
| MASS II (2006)8 | PCI | 205 | 60.0 | 67.0 | 23.0 | 52.0 | 67.0 | 100.0 | 85.0 | 74.0 | - | 28.0 | 2.35 | 72.0 | 0.0 | 5 | ***** |
| MT | 203 | 60.0 | 69.0 | 36.0 | 39.0 | 68.0 | 97.0 | 85.0 | 59.0 | - | 28.0 | 3.37 | |||||
| COURAGE (2007)5‘9 | PCI | 1149 | 61.5 | 85.0 | 32.0 | 38.0 | 60.8 | 95.0 | 85.0 | 93.0 | 42.0 | 62.0 | 1.9 | 94.0 | 3.0 | 4.6 | ***** |
| MT | 1138 | 61.8 | 85.0 | 35.0 | 39.0 | 60.9 | 94.0 | 86.0 | 93.0 | 52.0 | 65.0 | 2.0 | |||||
| FAME-2 (2018)3 | PCI | 447 | 63.5 | 79.6 | 27.5 | 37.1 | - | 90.2 | 68.3 | 90.2 | 29.3 | 78.0 | 93.9 | 97.0 | 95.0 | 5 | ****** |
| MT | 441 | 63.8 | 76.6 | 26.5 | 37.8 | - | 91.9 | 83.8 | 100.0 | 29.7 | 86.5 | 93.7 |
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BARI-2D: Bypass Angioplasty Revascularization 2 Diabetes; COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; CCB: calcium channel blockers; CRoB: Cochrane risk of bias; DES: drug-eluting stent; DM: diabetes mellitus; FAME: Fractional Flow Reserve versus Angiography for Multivessel Evaluation; LVEF: left ventricular ejection fraction; MASS: Medicine, Angioplasty or Surgery Study; MI: myocardial infarction; OAT: Occluded Artery Trial.
Scale constitutes of seven domains: random sequence generation (selection bias); allocation concealment (selection bias); blinding of participants and personnel (performance bias); blinding of outcome assessment (detection bias); incomplete data reporting (attrition bias); selective reporting (reporting bias) and other bias. Each domain carries one star and five or more stars represents good quality.